OrthoPediatrics Corp. Announces First Surgery Performed with Pediatric Nailing Platform | FEMUR

WARSAW, Ind., June 04, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the first surgery utilizing OrthoPediatrics’ newly launched rigid intramedullary nailing system, the Pediatric Nailing Platform|FEMUR (“PNP | FEMUR”), was performed on May 23, 2018 by Dr. Eric Gordon in St. Louis. Dr. Gordon, the original designer of OrthoPediatrics’ PediNail, served as a designing surgeon for the PNP|FEMUR system along with an internationally represented surgeon design team. The innovative system features two distinct child and adolescent implant offerings optimized for pediatric-specific anatomy and accompanied by an entire suite of new/enhanced high precision instrumentation. Capable of addressing trauma and deformity corrections alike, the first surgery performed with the new system represents the culmination of 18 months of development as the Company enters the next step in the evolution of its Intramedullary Nailing franchise.

The surgery performed was bilateral rotational osteotomies for excessive femoral anteversion, a procedure intended to correct a femur rotated too far forward, in a 13 year-old female. Each femur saw a 40-degree rotational correction achieved utilizing a 9mm Intramedullary Child Nail. After the case, Dr. Gordon stated, “The system’s innovative and pediatric-specific design allowed us to achieve superior results as the components fit smoothly together with ease. This is a substantial improvement in the ease of insertion and the anatomic fit, leading to an improved anatomic correction.  I am excited to offer my patients a better outcome and experience with this fantastic new system.”

Joe Hauser, Vice President of Trauma & Deformity Correction at OrthoPediatrics, commented, “We are incredibly pleased with the outcome of the first surgery and grateful for the opportunity to help this young patient. I’m especially thankful for the designing surgeons and engineers involved with this project and for their efforts in developing a system that treats a wider range of children and pathologies. This platform represents the next evolution of innovation from OrthoPediatrics, and I look forward to many more success stories.”

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 25 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 38 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

DT MedTech Announces the First US Implantations of the Hintermann Series H2® Total Ankle Replacement Prosthesis

BALTIMOREMay 31, 2018 /PRNewswire/ — DT MedTech, LLC (DTM) announced today that the first Hintermann Series H2® Total Ankle Replacement Systems have successfully been implanted in patients in the United States. Surgeries were performed, implanting the two-component, semi-constrained total ankle replacement prostheses, at The Johns Hopkins Hospital in Baltimore, Maryland by Dr. James Ficke, Director of Orthopaedic Surgery and Orthopaedist-in-Chief, and at Lakewood Ranch Medical Center in Sarasota, Florida by Dr. James Cottom of Florida Orthopedic Foot and Ankle Center.

The Hintermann Series H2® Total Ankle Replacement System is indicated to replace painful arthritic ankle joints due to primary osteoarthritis, post-traumatic osteoarthritis, or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis). The H2 may also be used as a revision for failed ankle replacements or non-union and mal-union of ankle arthrodesis. It is intended for cement use only in the US.

Prof. Beat Hintermann, world-renowned foot and ankle surgeon and developer of the H2, attended the surgeries and said, “I am extremely pleased to be here and observe the implantation of the first H2 ankles in the US. The surgeons did exemplary work and I am confident they will be very satisfied with their patients’ outcomes. The H2 design is based on the Hintermann H3* mobile-bearing ankle which has 18 years of positive clinical outcomes. I’m sure these ankles will prove to be the preferred ankle replacement prostheses for surgeons and patients in the United States and around the world.”

Dr. James Cottom observes, “I believe this implant will be a game changer in ankle arthroplasty and think future clinical studies will demonstrate that it is in a class of its own.”

David Reicher, President and Chief Executive Officer of DTM, stated, “We could not be more pleased with the H2 surgeries that have recently taken place. With the successful results experienced from more than 40 European implants, we’re confident the US success rates will be just as favorable. This exciting, complete ankle replacement system requires minimal bone resection and is designed to capture the axis of rotation which should result in highly reproducible outcomes. We feel it will significantly change the marketplace for primary and revision total ankle replacement surgeries on a global scale. Already available outside of the US, we expect a full US product launch in September of this year, as we continue to focus on intense training for our surgeons.”

About DT MedTech, LLC
DT MedTech, LLC is the parent company of DT MedTech International Limited and European Foot Platform, S.A.R.L. DTM and its subsidiary companies maintain offices in Baltimore, MarylandDublin, IrelandSaint-LouisFrance; and Liestal, Switzerland. As a member of the Data Trace family of businesses, leaders in scientific and medical publishing, surgical training, clinical trial management, medical malpractice insurance, and information services for more than 30 years, DTM provides innovative surgical solutions for lower extremity surgeons with state-of-the-art devices such as The Hintermann Series Total Ankle Replacement Systems.

*Please note: Hintermann Series H3™ is not available for sale or distribution within the United States and its territories.

Jeannie Sarda
DT MedTech, LLC
+1 410 427 0003


Organogenesis Comparative Effectiveness Research Demonstrating Faster VLU Time to Healing with Apligraf® Showcased at ISPOR

CANTON, Mass. and BALTIMOREMay 31, 2018 /PRNewswire/ — New comparative effectiveness research from Organogenesis Inc. demonstrating faster time to healing and greater healing rates with Apligraf® for the treatment of venous leg ulcers (VLUs) was showcased last week at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 meeting held May 19-23, 2018 in Baltimore, Maryland.

The research, “Comparative effectiveness of a bilayered living cellular construct and an acellular fetal bovine collagen dressing in the treatment of venous leg ulcers,” was e-published ahead of print in the peer-reviewed Journal of Comparative Effectiveness Research and showcased during a poster presentation at the meeting. The research was also among a select number of submissions to be considered for ISPOR’s Research Poster Awards. To view the published study online, please visit https://www.futuremedicine.com/doi/10.2217/cer-2018-0031.

“This is the first Comparative Effectiveness Research study that compares the clinical outcomes of a bilayer living cellular construct (BLCC) and an acellular fetal bovine collagen dressing (FBCD) for the treatment of VLUs in a real world setting,” said Michael Sabolinski, MD, lead author of the study. “Improvements in the probability, speed, and incidence of wound closure in VLUs treated with BLCC suggest a greater clinical benefit as well as a potential cost savings benefit.”

Using real-world data from the Net Health WoundExpert® database – the largest independent source of chronic wound benchmarking data in the industry – researchers compared clinical outcomes for the treatment of VLUs among two treatment modalities: Apligraf, a BLCC that is FDA-approved for the treatment of VLUs, and an acellular fetal bovine collagen dressing.

The study found that VLUs treated with Apligraf experienced a 37 percent faster median time to wound closure and that treatment with Apligraf increased the probability of healing by 45 percent when compared to VLUs treated with the acellular fetal bovine collagen dressing.

Chronic venous insufficiency affects approximately 2.5 million Americans, with up to 20 percent developing venous ulceration. Individuals who develop VLUs can often experience delayed healing and VLU recurrence. The impact on the patient’s quality of life and the economic cost of this disease can be significant; care for VLUs in the United States has been estimated to cost up to $3 billion annually1.

“Apligraf is the first approved bioengineered, living cell based product in the United States, and the only PMA approved skin substitute with the indication of healing venous leg ulcers,” said Shabnam Vaezzadeh, MD, MPA, Vice President of Global Medical and Clinical Affairs for Organogenesis Inc.  “Organogenesis is committed to empowering healing for patients with VLUs, elevating the global dialogue on health outcomes, and offering therapeutic solutions that facilitate positive clinical outcomes and reduce total cost of care.”

The leading global professional society for health economics and outcomes research, ISPOR is an international, multidisciplinary society dedicated to advancing the policy, science and practice of pharmacoeconomics and health outcomes research. An unbiased organization comprised of more than 9,500 members from 114 countries, ISPOR and its membership represent the entire field including research, academia, decision and policymaking, payer and patient communities.

About Organogenesis
Organogenesis Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

*De-identified patient data released to Organogenesis Inc. were consistent with the terms and conditions of Net Health’s client contracts and the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Net Health was not involved in the analysis, interpretation, or reporting of the data.

1 https://vascular.org/news-advocacy/venous-ulceration-minimally-invasive-treatment-big-problemJune 15, 2017 Dr. Paul DiMuzio – accessed on May 15, 2018.

Media Contact:
Angelyn Lowe
(781) 830-2353

SOURCE Organogenesis Inc.

NuVasive PRECICE STRYDE™ System Used In First Patient For Stature Lengthening By International Limb Lengthening Expert

SAN DIEGOMay 22, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the new PRECICE STRYDE™ system from NuVasive Specialized Orthopedics™ (NSO) was used in the first set of patients by internationally recognized limb lengthening and reconstruction expert Dr. Dror Paley. Built on five years of clinical experience, PRECICE STRYDE is a market-leading internal system available for stature lengthening and limb reconstruction.

PRECICE STRYDE is NSO’s third-generation limb lengthening system and includes an implantable intramedullary nail, locking screws, reusable instruments and a hand-held External Remote Controller (ERC). STRYDE was recently cleared by the U.S. Food and Drug Administration in April for use in both the tibia and femur. Patients are now able to non-invasively lengthen or shorten the implant to a prescribed length utilizing the ERC post-surgery from their own home versus lengthy hospital stays. When used for stature lengthening for cosmetic purposes, STRYDE can increase a patient’s height by more than three inches.

Dr. Paley is the founder and director of the Paley Orthopedic & Spine Institute in West Palm Beach, Fla., and is recognized as one of the most experienced surgeons in the United States and world in limb lengthening and deformity correction.

“The PRECICE STRYDE technology advances how I am able to treat patients requiring limb reconstruction or those seeking to increase their height, and I am excited to incorporate this into my practice,” said Dr. Paley, a board-certified orthopedic surgeon specializing in limb lengthening and deformity correction. “I continually seek to offer better clinical solutions to my patients, and I am proud to have collaborated with NuVasive in the development of this latest orthopedic advancement.”

This new system aims to provide better and more tolerable post-operative outcomes for patients undergoing limb lengthening. Prior to this technology, a patient was only permitted to apply 30-50 pounds of weight on each leg, leading to a slow and lengthy return to daily life and activities. With STRYDE’s unique stainless steel composition, patients are now able to apply 150-250 pounds of weight on each leg depending on the device chosen and post-operative care recommended by their physician. This offers patients a potential for 200 percent or greater post-operative weight-bearing activity compared to previous systems, and studies have shown earlier weight bearing may lead to quicker healing times in patients using the PRECICE system1. Next launch steps include partnering with leading global limb lengthening surgeons to demonstrate cosmetic stature lengthening viability with plans for a limited launch in mid-2018 and the product more broadly available in 2019.

“At NSO, we are excited to introduce PRECICE STRYDE to the market, which is just the start of a long line of PRECICE products in the next 18-months to further transform the orthopedic space and offer better clinical outcomes for patients,” said Massimo Calafiore, president of NSO. “There is so much opportunity for us to address unmet clinical needs in the orthopedic market—from limb reconstruction to stature lengthening—this latest technology has the ability to drastically improve how our surgeon partners treat their patients.”

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

1 Laubscher M, Mitchell C, Timms A, et al. Outcomes following femoral lengthening: An initial comparison of the PRECICE intramedullary lengthening nail and the LRS external fixator monorail system. Bone Joint J 2016;98-B:1382–8.


SOURCE NuVasive, Inc.

Related Links


CrossRoads® Extremity Systems Announces Launch of the Active Stabilization™ MPJ Implant System

MEMPHIS, Tenn.May 22, 2018 /PRNewswire/ — CrossRoads® Extremity Systems, the Global Leader in Active Stabilization™, offering innovative foot & ankle fixation implant systems and services, announced that the Company has received FDA clearance for the DynaFORCE® Active Stabilization™ MPJ Implant System. CrossRoads® Extremity Systems has the only MPJ Implant system on the market that combines stability of an anatomic plate with active compression of a nitinol clip, delivered to the operating room completely sterile packed.

Scott Shawen, MD, from Charlotte, NC, one of the first users of the MPJ Active Stabilization™ system states, “CrossRoads provides a comprehensive Active Stabilization™ system that is easy to use. After more than 30 cases, I have found that the instrumentation is the most ergonomic on the market, making drilling and deployment of the compression clip and plate quick and simple.” He continued to say, “Anecdotally, my midfoot fusion times have been cut in half. Additionally, my patients have earlier initiation of weight bearing. I look forward to using DynaFORCE® Active Stabilization™ constructs on additional applications in the future.”

About CrossRoads® Extremity Systems

CrossRoads was founded in 2014 and is headquartered in Memphis, TN. CrossRoads has experienced rapid growth through creative product development and a strong distributorship network. CrossRoads’ goal is to provide a steady rhythm of novel and clinically relevant new products that distinguish it from other companies.

In addition to providing novel products, CrossRoads strives to find ways to help hospitals save money and improve efficiency. CrossRoads believes that as customers experience the EcoSMART® model of using high quality, surgical grade instruments in sterile kits, EcoSMART® Service will become the preferred model of surgeons, O.R. staff, and materials management.

For more information, please visit www.crextremity.com or www.activestabilization.com

©2018 CrossRoads Extremity Systems, LLC.  All Rights Reserved

Vernon Hartdegen
President & CEO of CrossRoads Extremity Systems, LLC

SOURCE CrossRoads Extremity Systems

Related Links


Globus Medical Announces Appointment of Orthopedic Trauma Division’s Vice President of Sales

AUDUBON, Pa., May 21, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the appointment of Daniel Gregoris to Vice President of Sales for the company’s emerging Orthopedic Trauma division.  Gregoris will be responsible for leading the growth and expansion of Globus Medical’s direct Trauma sales force and the development and execution of all domestic sales strategies within the Trauma business unit.

“Dan shares the company’s values and passion for continuous product innovation and exceptional customer responsiveness,” said Chief Executive Officer Dave Demski.  “His extensive experience in sales management, expertise in the orthopedic trauma space, and proven track record of building dynamic and highly successful sales teams make him an excellent choice to lead our trauma sales force as they enter this new market.”

Prior to joining Globus Medical, Gregoris served as Area Vice President of Sales for DePuy Synthes Trauma, a subsidiary of Johnson and Johnson, and brings over 20 years of combined sales and sales management experience in the orthopedic trauma market.

“I’m so excited to lead the trauma sales efforts for a company with a strong history in quality products and service that truly help surgeons and healthcare systems advance patient care,” Gregoris said. “I am passionate about medical devices and this is where I have spent my entire career. I look forward to leveraging my more than two decades of sales experience and relationships with the Globus commitment to enter and advance orthopedic trauma.”

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email:  investors@globusmedical.com

Amplitude Surgical Granted the Euronext Tech 40 Label

May 18, 2018

VALENCE, France–(BUSINESS WIRE)–Regulatory News:

Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker: AMPLI, PEA-PME eligible), a leading French player on the global surgical technology market for lower-limb orthopedics, announces that it has joined the list of innovative companies listed on the Euronext comprising the “Tech 40” label.

Launched in April 2015 on EnterNext’s initiative, this label incorporates emblematic Tech sector companies listed on the Euronext markets in Paris, Amsterdam, Brussels and Lisbon that operate in one of the following fields of activity: life sciences, eco-industries or TMT. The 40 companies granted this label are selected by an independent group of European experts based on their business, financial and stock market performance.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says: “All of Amplitude Surgical’s staff and I, founder of the Group in 1997, are particularly proud to be joining the other technological players listed on the Euronext that have been granted this label. This TECH 40 label rewards the hard work undertaken by our teams to implement a winning growth strategy, based on an international deployment and a portfolio of innovative products.”

About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2017, Amplitude Surgical had a workforce of nearly 370 employees and recorded sales of over 93 million euros.


Amplitude Surgical
Philippe Garcia
+33 (0)4 75 41 87 41
Investor Relations
Marc Willaume
+33 (0)1 44 71 00 13
Media Relations
Nicolas Merigeau
+33 (0)1 44 71 98 55

DJO Announces Appointment of Mark Dorris as President, Bracing and Supports

May 16, 2018

SAN DIEGO–(BUSINESS WIRE)–DJO (“DJO” or the “Company”), a leading global provider of medical technologies designed to get and keep people moving, today announced the appointment of W. Mark Dorris as President of Bracing and Supports, DJO’s largest business unit.

Mr. Dorris is a seasoned executive with more than 30 years of experience in the healthcare industry, most recently serving as the President of Zimmer Surgical for seven years, where he significantly grew revenue and operating profit. Prior to Zimmer, Mr. Dorris was the President of Medegen Medical Products, a private equity portfolio business of Nautic Partners, where he oversaw all functional areas and execution of an aggressive acquisition strategy. He has held positions of increasing responsibility in sales and marketing, including Vice President, Marketing at Tyco Healthcare during his 15 years there. Mr. Dorris began his career in sales at Johnson & Johnson.

Mr. Dorris received a Bachelor of Science in Business Management from Western Kentucky University.

“I’m confident that Mark’s history of commercial success, operational excellence and keen understanding of the orthopedic space will significantly accelerate the performance of our BAS business,” said Brady Shirley, DJO’s President and Chief Executive Officer.

“I couldn’t be more excited to join DJO at this pivotal point in the Company’s growth trajectory,” said Mr. Dorris. “DJO’s Bracing & Supports business continues to expand market and mind share with its flagship brands of DonJoy® and Exos®. With the recent introduction of the cloud-based X4™ Smart Brace with Motion Intelligence™, and a robust innovation pipeline, DJO understands the power of blending technology, quality and results to ensure our customers’ around the world get and keep moving.”

About DJO

DJO is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation, enabling people to regain or maintain their natural motion. Its products are used by orthopaedic surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopaedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™. For additional information on the Company, please visit www.DJOglobal.com.


DJO Media Contact:
Brittany Knudson
Sr. Director, Marketing Communications
DJO Investor Contact:
David Smith
SVP, Treasurer and Investor Relations

Medical Devices with Aptitude: How Smart Implants Improve Patient Outcomes

S. Himmelstein – 09 May 2018

Traditionally manufactured implants have their limitations, as they can only be produced in a certain number of shapes and sizes, posing problems in terms of patient fit. Joint replacement devices can be agents of stress shielding — the process whereby metal implants remove stress from the patient’s bone, which responds by reducing in density and becoming weaker. Cardiac implants require routine removals to replace batteries.

What’s a medical device designer to do? Make the implants smarter. The smart implant is medicine’s latest innovation, a tiny chip implanted in surgery which is able to measure patients’ pH and hormone levels, blood glucose concentration, bacteria, electrical activity and temperature, providing doctors with real-time biofeedback. Patients equipped with smart implants have a lower risk of serious infection post-op, suffer from less discomfort and pain, and could also be less likely to need revision surgeries in the future.

The advent of additive manufacturing offers a route to the design of patient-specific implants (PSIs). The manufacturing method also imposes fewer geometric constraints than subtractive manufacturing. PSIs designed and manufactured according to a patient’s computed tomography scan encourages the implant to integrate with the patient’s bone, reducing the risk of loosening. The use of 3D printing enables surgeons to control additional material properties and design implants that mimic a patient’s bone stiffness, density and trabecular structure, which can reduce stress shielding and improve physical function.

The European Union’s PRosPERoS (PRinting PERsonalized orthopedic implantS) research project is developing smart, 3D-printed implants for the repair of large bone defects. Personalized and biodegradable implants are being engineered based on magnesium and zinc alloys. By accurately scanning the vertebrae with advanced imaging techniques, PSI implants can be designed and printed.

Built-in sensors represent another opportunity for smartening up implants. Advanced sensor technology is fostering development of implants that can detect an infection and subsequently secrete the appropriate dose of antibiotic. Sensors can measure the strain exerted on the implant, which indicates the extent the fracture has healed.





Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress

May 08, 2018

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its innovative commercial and pipeline portfolio at the 18th bi-annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) Congress, being held in Glasgow, Scotland on May 9-12, 2018.

“We look forward to showcasing our pioneering orthopedic and regenerative medicine solutions, including CINGAL and HYALOFAST, at the 18th ESSKA Congress,” said Joseph Darling, President and CEO, Anika Therapeutics. “Our participation represents an important opportunity to highlight real-world evidence from CINGAL and HYALOFAST to the 4,000 medical experts in the field of sports traumatology, knee surgery and arthroscopy participating from all over the world.”

Company-Sponsored Physician Education
Location: Anika Booth #51, Hall no.4, Scottish Event Campus

Wednesday, May 9, 2018

  • 10:00 – 11:00 Dr. Mikolaj Wrobel, OrtopediKa Clinic in Warsaw, Poland, will be available at the booth for guided training sessions with the HYALOFAST Virtual Surgical Simulator.

Thursday, May 10, 2018

  • 15:30 – 16:30 Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy, will be available at the booth for guided training sessions with the HYALOFAST Virtual Surgical Simulator.

Company-Sponsored Lunch Symposium
Location: Room Boisdale 1/2, Scottish Event Campus

Friday, May 11, 2018

  • 12:30 – 13:30 Boisdale 1/2 Room, Lunch Symposium: HYALOFAST One-step Procedure: Best Practice and New Evidence in Cartilage Repair
    Moderator: Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy

Speakers and Topics:

  • Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy: HYALOFAST Long-Term Clinical Outcomes in the Treatment of Full-Thickness Cartilage Lesions of the Knee
  • Dr. Bogusław Sadlik, St. Luke Clinic, Bielsko Biala – Poland: HYALOFAST Arthroscopic Implantation in the Knee: Pitfalls, Pearls and MRI Based Rehab Protocol
  • Prof. Stephan Nehrer, Danube University, Krems – Austria: HYALOFAST in the Treatment of Cartilage Defects in the Ankle: Surgical Technique and Clinical Results

About ESSKA Congress

The 18th ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) Congress is expected to include 4,000 medical experts in the field of sports traumatology, knee surgery and arthroscopy from all over the world. It offers many opportunities to interact with orthopedic surgeons, physio therapists and other medical professionals.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.


Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer